Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force.
Journal
Bipolar disorders
ISSN: 1399-5618
Titre abrégé: Bipolar Disord
Pays: Denmark
ID NLM: 100883596
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
12
8
2022
medline:
5
10
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions. We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and Clinicaltrials.gov from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist. We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as 'fair'. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred. Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
Sections du résumé
BACKGROUND
Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions.
METHODS
We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and Clinicaltrials.gov from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist.
RESULTS
We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as 'fair'. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred.
CONCLUSIONS
Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
Identifiants
pubmed: 35950925
doi: 10.1111/bdi.13247
pmc: PMC9826389
doi:
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-636Informations de copyright
© 2022 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
Références
Mol Psychiatry. 2018 May;23(5):1127-1133
pubmed: 28533517
Neuroimage. 2019 Jul 15;195:475-489
pubmed: 30954710
J Affect Disord. 2021 Feb 15;281:776-785
pubmed: 33246649
Bipolar Disord. 2017 Dec;19(8):614-626
pubmed: 28895274
Curr Opin Pharmacol. 2014 Feb;14:54-61
pubmed: 24565013
J Psychiatry Neurosci. 2017 May;42(3):150-163
pubmed: 27780031
Bipolar Disord. 2022 Sep;24(6):615-636
pubmed: 35950925
Front Pharmacol. 2021 Jan 21;11:618184
pubmed: 33551817
Philos Trans R Soc Lond B Biol Sci. 2021 Jan 4;376(1815):20190630
pubmed: 33190598
Psychopharmacology (Berl). 2012 Oct;223(4):417-25
pubmed: 22555622
Acta Psychiatr Scand. 2016 Sep;134(3):249-59
pubmed: 27259062
Int J Neuropsychopharmacol. 2020 May 27;23(5):287-299
pubmed: 32055822
Trends Cogn Sci. 2018 Jan;22(1):8-20
pubmed: 29167088
Neuroimage. 2008 Apr 1;40(2):409-414
pubmed: 18191585
Neuropsychopharmacology. 2021 May;46(6):1113-1121
pubmed: 33168945
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Apr 20;91:94-102
pubmed: 30125624
Radiology. 2016 Nov;281(2):516-526
pubmed: 27351678
Eur Neuropsychopharmacol. 2017 Apr;27(4):399-410
pubmed: 28291572
Psychopharmacology (Berl). 2014 Oct;231(19):3879-88
pubmed: 24643507
Hum Brain Mapp. 1999;8(2-3):102-8
pubmed: 10524600
Nat Rev Drug Discov. 2012 Feb 01;11(2):141-68
pubmed: 22293568
Hippocampus. 2019 Jul;29(7):595-609
pubmed: 30447076
CNS Spectr. 2021 Aug;26(4):333-337
pubmed: 32122432
Biol Psychiatry. 2012 Dec 1;72(11):943-9
pubmed: 22770649
Schizophr Bull. 2015 Nov;41(6):1276-84
pubmed: 25800249
Neuroimage. 2010 Aug 15;52(2):658-68
pubmed: 20399274
Acta Psychiatr Scand. 2021 Feb;143(2):151-161
pubmed: 33089491
Neural Plast. 2018 Dec 31;2018:3419871
pubmed: 30693023
J Clin Psychiatry. 2014 Dec;75(12):1347-55
pubmed: 25099079
CNS Spectr. 2019 Feb;24(1):30-53
pubmed: 30198479
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Aug;4(8):688-696
pubmed: 31072761
Sci Rep. 2017 Sep 4;7(1):10401
pubmed: 28871117
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Neuroimage. 2012 Apr 15;60(3):1746-58
pubmed: 22330316
J Psychopharmacol. 2018 Oct;32(10):1075-1085
pubmed: 29969938
Psychol Med. 2014 Oct;44(14):3083-96
pubmed: 25065409
PLoS One. 2018 Nov 8;13(11):e0206583
pubmed: 30408072
Br J Pharmacol. 2013 Sep;170(1):144-55
pubmed: 23517178
J Psychopharmacol. 2020 Sep;34(9):981-989
pubmed: 32762272
Psychopharmacology (Berl). 2006 Apr;185(3):339-47
pubmed: 16525858
J Affect Disord. 2016 Nov 15;205:378-386
pubmed: 27573491
Schizophr Bull. 2021 Oct 21;47(6):1557-1600
pubmed: 34097043
Neuroimage. 2021 May 15;232:117913
pubmed: 33657450
Biol Psychiatry. 2015 Aug 15;78(4):270-7
pubmed: 25641635
Br J Psychiatry. 2017 Jan;210(1):54-60
pubmed: 27284082
Psychol Med. 2018 Dec;48(16):2717-2729
pubmed: 29679991
Bipolar Disord. 2022 Feb;24(1):69-81
pubmed: 33955648
PLoS One. 2016 Jul 22;11(7):e0158867
pubmed: 27448153
Neuroimage. 2008 Aug 1;42(1):196-206
pubmed: 18538585
Bipolar Disord. 2021 Aug;23(5):487-499
pubmed: 33053258
Neuropsychology. 2006 Sep;20(5):497-510
pubmed: 16938013
J Neurosci. 2011 Aug 24;31(34):12139-48
pubmed: 21865456
CNS Drugs. 2013 Aug;27(8):663-73
pubmed: 23794107
Acta Psychiatr Scand. 2021 Oct;144(4):379-391
pubmed: 34245569
Psychoneuroendocrinology. 2021 Mar;125:105116
pubmed: 33418240
Psychol Med. 2017 Jul;47(10):1848-1864
pubmed: 28241891
Neurosci Biobehav Rev. 2015 Apr;51:77-86
pubmed: 25597656
Neuropsychopharmacology. 2007 May;32(5):1011-20
pubmed: 17063156
Transl Psychiatry. 2013 Jul 16;3:e282
pubmed: 23860483
Eur Neuropsychopharmacol. 2019 Mar;29(3):319-329
pubmed: 30654916
BMC Neurosci. 2010 Sep 16;11:118
pubmed: 20846444
Front Hum Neurosci. 2015 Dec 21;9:681
pubmed: 26733852
Psychol Med. 2016 Jun;46(8):1679-91
pubmed: 26996196
J Affect Disord. 2013 Sep 5;150(2):551-8
pubmed: 23453674
Hum Psychopharmacol. 2018 Sep;33(5):e2675
pubmed: 30306671
Neurosci Bull. 2019 Oct;35(5):867-876
pubmed: 31062333
J Neurosci. 2013 Apr 17;33(16):7050-6
pubmed: 23595762
Front Behav Neurosci. 2015 Sep 04;9:244
pubmed: 26388754